Swiss biotech R&D expenses 2025| ��ƽ��

Swiss biotech companies' research and development expenses from 2016 to 2025 (in million Swiss francs)

Characteristic	Total	Public biotech companies	Private biotech companies
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-
-	-	-	-

Download

Source

Show detailed source information?

Already a member?

Sources

Release date

April 2026

More information

Region

Switzerland

Survey time period

2016 to 2025

Supplementary notes

As some privately held companies do not disclose financial figures, the figures represent EY’s best estimate. All figures are headquarter-counted and do not include data from pharma companies such as Novartis and Roche.

Citation formats

In 2025, Swiss biotech companies invested nearly 2.5 billion Swiss francs in research and development.

Swiss biotech and pharma companies

Swiss biotech companies have increased their research and development (R&D) expenses from **** billion Swiss francs in 2015 to *** billion Swiss francs in 2025. The amounts spent by public and private companies were around **** billion and **** billion francs, respectively. There are around *** Swiss companies that use biotechnological technologies to develop products. Many are located around Lake Geneva, the Greater Basel Area, and the Greater Zurich Area.

Swiss company Novartis is one of the world’s largest biopharmaceutical companies based on prescription sales, generating over ** billion U.S. dollars in 2024; in comparison, research and development spending totaled about *** billion U.S. dollars. Novartis was established in 1996 when the companies Ciba-Geigy and Sandoz Laboratories were merged. Currently, the company is headquartered in Basel, and its campus includes works from a variety of artists and architects. Novartis' total revenues are dominated by its Innovative Medicines segment, reporting over ** billion U.S. dollars in 2025.